Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Valvular regurgitation represents an important cause of cardiovascular morbidity and
mortality. Imaging is pivotal in the evaluation of native valve regurgitation and …

Nearly half of all patients with heart failure (HF) have a normal left ventricular (LV) ejection
fraction (EF) and the condition is termed heart failure with preserved ejection fraction …

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF)
remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA–PEFF …

Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant
form of heart failure worldwide, in tandem with ageing of the general population and the …

The “Guidelines on the Management of Valvular Heart Disease” were initially published as
the “Guidelines on Non-pharmacological Treatment of Valvular Heart Disease” in 2002 …

Since the 2007 publication of the American Society of Echocardiography (ASE) guidelines
for stress echocardiography, 1 new information has become available about the …

Cirrhotic cardiomyopathy (CCM) is cardiac dysfunction in patients with end‐stage liver
disease in the absence of prior heart disease. First defined in 2005 during the World …